Searchable abstracts of presentations at key conferences in endocrinology

ea0078p14 | Diabetes | BSPED2021

Level 3 Carbohydrate counting at diagnosis of Type I Diabetes Mellitus in children: How does it affect HbA1c?

Barber Wendy , Keeton Emma , Taylor Adele

Introduction: National guidance recommends Level 3 carbohydrate counting (L3CC) is delivered within 2 weeks of diagnosis of Type I Diabetes Mellitus (T1DM) (NICE, 2015). This was introduced at Derbyshire ChildrenÂ’s Hospital in 2017. This service evaluation aimed to assess the impact of this on patientsÂ’ blood glucose, by recording HbA1c levels at quarterly intervals over 6 months. Methods: A comparison of quarterly HbA1c in children that receiv...

ea0050ep054 | Diabetes and Cardiovascular | SFEBES2017

Significant improvement in response to the GLP1-agonist 'Liraglutide' following change in injection site

Border Daniel , Clayton Wendy , Barber Tom , Randeva Harpal

Variability in treatment response with respect to GLP1 agents is well-accepted but incompletely understood. In a specialist GLP-1 clinic at UHCW, we describe a case of improved therapeutic response following change in injection site. Currently, advice is injection in the abdomen or thigh.A 61 year old man was commenced on Liraglutide 1.2 mg subcutaneous OD injection, in 2013. Previously managed with glimepiride 4 mg and ...

ea0050ep054 | Diabetes and Cardiovascular | SFEBES2017

Significant improvement in response to the GLP1-agonist 'Liraglutide' following change in injection site

Border Daniel , Clayton Wendy , Barber Tom , Randeva Harpal

Variability in treatment response with respect to GLP1 agents is well-accepted but incompletely understood. In a specialist GLP-1 clinic at UHCW, we describe a case of improved therapeutic response following change in injection site. Currently, advice is injection in the abdomen or thigh.A 61 year old man was commenced on Liraglutide 1.2 mg subcutaneous OD injection, in 2013. Previously managed with glimepiride 4 mg and ...